Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBT Margin (2017 - 2025)

Historic EBT Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 16.97%.

  • Puma Biotechnology's EBT Margin fell 86200.0% to 16.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.58%, marking a year-over-year increase of 44600.0%. This contributed to the annual value of 10.46% for FY2024, which is 8300.0% up from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's EBT Margin is 16.97%, which was down 86200.0% from 11.76% recorded in Q2 2025.
  • Puma Biotechnology's 5-year EBT Margin high stood at 25.59% for Q3 2024, and its period low was 96.52% during Q3 2021.
  • Moreover, its 5-year median value for EBT Margin was 7.1% (2025), whereas its average is 1.01%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -345300bps in 2021, then skyrocketed by 960100bps in 2022.
  • Puma Biotechnology's EBT Margin (Quarter) stood at 8.01% in 2021, then tumbled by -176bps to 6.06% in 2022, then surged by 393bps to 17.74% in 2023, then increased by 17bps to 20.72% in 2024, then decreased by -18bps to 16.97% in 2025.
  • Its EBT Margin stands at 16.97% for Q3 2025, versus 11.76% for Q2 2025 and 7.1% for Q1 2025.